-
The ranking of TOP10 antidepressants has changed!
Time of Update: 2021-06-11
Recently, Shanghai Shangyao Zhongxi Pharmaceutical's duloxetine hydrochloride enteric-coated tablets was approved for supplementary application, and it was the first company to have reviewed the product; Hainan Herui Pharmaceuticals used generic 4 types of venlafaxine hydrochloride to be produced.
-
Another listed pharmaceutical company transforms into healthcare!
Time of Update: 2021-06-11
Changed to "Jimin Medical", the company's full name and securities code remain unchanged, and the date of change of the securities abbreviation is June 4, 2021.
-
The notice regarding the full implementation of the new drug application information on drug listing and open bargaining procurement is here!
Time of Update: 2021-06-11
On May 31, Shanghai Sunshine Pharmaceutical Purchasing Network released the information publicity (the thirteenth batch) of new drug applications for the full implementation of open drug bargaining procurement on the Internet.
-
16 provincial-level pharmaceutical groups have begun to purchase and report for volume!
Time of Update: 2021-06-11
According to feedback, the Shenzhen Municipal Medical Insurance Bureau issued a notification on the 27th: "Notice on Filling in the Pre-purchasing Volume of Related Drugs Procured by Provincial Pharmaceutical Groups in 2021", requiring the breakdown of medical insurance, relevant medical institutions, and designated retail pharmacies Fill in the unified online reporting system on the provincial platform.
-
Levofloxacin intermediates and APIs of East Asia Pharmaceuticals passed Japanese GMP certification
Time of Update: 2021-06-11
The company's GMP certification by PMDA can also promote the company's sales of levofloxacin APIs and intermediates in other overseas markets.
-
Merck’s 25 billion blockbuster drug domestic cancellation approval, AbbVie once starred hepatitis C drug from the market...
Time of Update: 2021-06-11
Generic drugs are forcing the original drugs to be withdrawn from the market. On May 24, the State Food and Drug Administration issued a batch of drug registration certificate revocation announcements
-
The rapid development report of the medical and health industry analyzes the challenges of public medical institutions
Time of Update: 2021-06-11
Specifically, at the policy level, the reform of payment methods and " purchasing with volume ", which are mainly related to disease diagnosis , have had a profound impact on the industry’s traditional commercial and Companies have entered the medical and health industry across borders.
-
Qilu imatinib mesylate tablets will be approved soon
Time of Update: 2021-06-11
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with imatinib mesylate tablets reported for production in category 4 imitations.
At present, CSPC Ouyi, Hausen, and Novartis have approved the production of imatinib mesylate tablets in China.
-
The fifth batch of nationally sourced two varieties were eliminated!
Time of Update: 2021-06-11
However, there are differences in the rules for determining the first-year contracted purchase amount for each product and region, for azithromycin injection, fluconazole injection, linezolid glucose injection, moxifloxacin eye drops, tinidazole oral regular-release dosage form, etc.
-
Summary of the review of the fifth batch of nationally-sourced varieties in May
Time of Update: 2021-06-11
On May 8, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Carrying out the Fifth Batch of National-organized Drug Centralized Procurement of Drug Information Collection Work".
-
Beijing Tide Pharmaceutical won the annual charity model of the 2021 China Charity List
Time of Update: 2021-06-11
was awarded the honorary title of "2021 China Charity List Annual Charity Model" for its active performance and outstanding contribution during the new crown pneumonia epidemic.
-
The pediatric Chinese patent medicine market has shrunk TOP10 products who are the most resistant to stress?
Time of Update: 2021-06-11
Figure 1: The share of the seven subcategories of pediatric Chinese patent medicines in 2020 (unit: %) Source: Mi Nei Net Database In terms of subcategories, pediatric cold medications and pediatric cough and expectorant medications are the two subcategories with the largest proportions, both at the terminals of public medical institutions in China and physical pharmacies in cities in China, but they are also the two most affected by the epidemic.
-
Sichuan pharmaceutical company will win the blockbuster first to imitate the $1.4 billion variety to welcome the first production company
Time of Update: 2021-06-11
Recently, the first generic drug R&D welcome progress: Hainan Simcere is the first to submit a generic drug listing application for idoxaban tosylate tablets, and Sichuan Pride Times Pharmaceuticals uses generic 3 types of telmisartan and amlodipine tablets for production Enter the stage of administrative approval.
-
The fifth round of national procurement of these pharmaceutical companies to enter
Time of Update: 2021-06-11
The fifth batch of national procurement, the competitive landscape continues to change, and many pharmaceutical companies enter the gameA number of pharmaceutical companies entered the fifth batch of
-
The latest list of pharmaceutical companies announced: Qilu, Kelun, CSPC...
Time of Update: 2021-06-11
On January 29, Qilu Pharmaceutical was approved for the production of metformin and vildagliptin tablets for generic 4 types of applications and was deemed to have been reviewed, becoming the first imitation in China.
-
The list of the 15 highest paid pharmaceutical company executives in the world in 2020 announced
Time of Update: 2021-06-11
In the past year, the epidemic has swept the world, and the salary of executives of multinational pharmaceutical companies involved in the development of vaccines and therapeutics has also been affected.
-
ASC40 combined with bevacizumab was approved for clinical treatment of rGBM patients
Time of Update: 2021-06-11
Gale Pharmaceuticals announced today that after communication with the National Medical Products Administration of China, the clinical trial application of ASC40 combined with bevacizumab for the treatment of patients with recurrent glioblastoma (rGBM) has been accepted.
-
Jointly issued by the Drug Administration of the two provinces!
Time of Update: 2021-06-11
The party’s use of unqualified polyester/aluminum/polyethylene medicinal composite film (batch number 2003079) violated Article 2 of the "Management Measures for Packaging Materials and Containers in Direct Contact with Drugs" (Bureau Order No.
-
For severe alopecia areata!
Time of Update: 2021-06-11
Article source: Pharmaceutical GuanlanOn June 2, the China Drug Clinical Trial Registration and Information Disclosure Platform showed that Zejing Pharmaceuticals launched a Phase 3 clinical trial of Jacketinib Hydrochloride Tablets for the treatment of severe alopecia areata.
-
Good news for patients with hyperammonemia, domestic sodium phenylbutyrate powder will be approved soon
Time of Update: 2021-06-11
A few days ago, the marketing application of Zhaoke Pharmaceutical's 3 generic drug sodium phenylbutyrate powder (the relevant acceptance number is CYHS1800114) entered the administrative review stage, and it is expected that it will be formally approved soon for the adjuvant treatment of carbamoyl phosphate synthase ( CPS), ornithine transcarbamylase (OTC) or argininosuccinate synthetase (AS) deficiency caused by chronic urea cycle disorder (UCD) caused hyperammonemia.
